Neurocrine Biosciences Inc. filings document the regulatory record of a commercial biopharmaceutical company developing and selling treatments for neurological, psychiatric, endocrine and immunological disorders. Its 8-K reports cover operating and financial results, product-sales disclosures, clinical or regulatory updates, material agreements, capital-structure matters and executive or employment-related governance events.
Proxy filings describe board matters, shareholder voting items, executive compensation, equity awards and pay-versus-performance disclosures. The filing record also includes formal disclosures related to INGREZZA, CRENESSITY and the company's pipeline, as well as risk, governance and transaction-related disclosure categories relevant to its public-company status.
NEUROCRINE BIOSCIENCES INC Chief Regulatory Officer Ingrid Delaet reported an option exercise combined with a routine share sale. On May 29, 2026, she exercised non-qualified stock options for 2,261 shares of common stock at an exercise price of $79.02 per share and sold 2,261 shares in an open-market transaction at $156.71 per share. After these transactions, she directly held 16,225 shares of common stock. The sale was executed by a broker under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026, which company policy does not allow her to amend or modify after adoption.
Notification of proposed sale of Common Stock under Rule 144. The filing lists 24,965 shares of Common Stock to be sold on 06/02/2026 described as resulting from an Exercise of Stock Options. The report also lists 9,879 Restricted and Performance Stock Units (02/08/2021) and 2,093 previously exercised stock options (08/04/2020).
The broker is listed as Morgan Stanley Smith Barney LLC and the execution venue is shown as NASDAQ.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice reporting the proposed sale of 11,000 shares of Common Stock tied to an Exercise of Stock Options dated 06/01/2026. The filing shows associated dollar amounts of $1,741,300.00 and $1,710,865.20, and references 10b5-1 sales activity on 05/27/2026.
Neurocrine Biosciences Chief Scientific Officer Jude Onyia exercised options for 11,000 shares of common stock at $84.74 per share and, on the same day, sold 11,000 shares in open-market transactions at a weighted average price of $155.5332 per share.
The sale was carried out by a broker under a pre-arranged Rule 10b5-1 trading plan adopted on February 25, 2026. Following these transactions, Onyia directly holds 25,846 shares of common stock and 24,268 non-qualified stock options.
NEUROCRINE BIOSCIENCES INC director Kevin Charles Gorman received a new stock option grant. He was awarded options on 5,248 shares of common stock at an exercise price of $155.83 per share. The options vest in 12 monthly installments beginning June 27, 2026 and expire on May 27, 2036.
POPS RICHARD F reported acquisition or exercise transactions in this Form 4 filing.
NEUROCRINE BIOSCIENCES INC director Richard F. Pops received a grant of 2,567 Restricted Stock Units (RSUs). Each RSU represents one share of common stock upon vesting, and all 2,567 RSUs are scheduled to vest in full on May 27, 2027. Following this compensation award, Pops holds 2,567 RSUs directly.
NEUROCRINE BIOSCIENCES INC director Gary A. Lyons received new equity awards as part of his compensation. On May 27, 2026, he was granted non-qualified stock options for 2,624 shares of common stock at an exercise price of $155.83 per share, vesting in 12 monthly installments beginning June 27, 2026.
He also received 1,284 Restricted Stock Units, each representing one share of common stock upon vesting. These RSUs will vest in full on May 27, 2027. The filing shows these as direct holdings and reflects routine, compensation-related acquisitions rather than open-market buying or selling.
Mercier Johanna reported acquisition or exercise transactions in this Form 4 filing.
Neurocrine Biosciences director Johanna Mercier received a grant of 2,567 restricted stock units (RSUs). Each RSU represents the right to receive one share of Neurocrine Biosciences common stock upon vesting. The RSUs will vest in full on May 27, 2027, and her direct holdings after this grant total 2,567 RSUs.
POON CHRISTINE A reported acquisition or exercise transactions in this Form 4 filing.
NEUROCRINE BIOSCIENCES INC director Christine A. Poon reported an equity compensation grant of 2,567 Restricted Stock Units. Each RSU represents one share of common stock upon vesting, and the entire award is scheduled to vest in full on May 27, 2027.
Sharp Shalini reported acquisition or exercise transactions in this Form 4 filing.
Neurocrine Biosciences director Shalini Sharp received a grant of 2,567 restricted stock units (RSUs). Each RSU represents one share of common stock upon vesting, and the entire award will vest on May 27, 2027. This is a stock-based compensation grant, not an open-market share purchase or sale, and leaves her with 2,567 RSUs reported as directly held.